Actively Recruiting

Phase 3
Age: 18Years +
All Genders
NCT06925321

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Led by Basilea Pharmaceutica · Updated on 2026-04-22

234

Participants Needed

49

Research Sites

127 weeks

Total Duration

On this page

Sponsors

B

Basilea Pharmaceutica

Lead Sponsor

B

Biomedical Advanced Research and Development Authority

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to evaluate the efficacy and safety of fosmanogepix (administered IV or oral) for the treatment of adult patients with invasive mold infections. The study is looking for patients who have been diagnosed with invasive mold infections. The maximum study duration will be approximately 8 months, including a target study treatment duration of 84 days which can be extended up to 180 days and follow-up period. The patient will be assigned to one of two treatment cohorts: Cohort A (primary therapy): Patients will receive either the study drug or institutional standard of care antifungal treatment. Cohort B (salvage treatment; i.e. treatment given after patients did not respond to previous treatments or did not tolerate them): Patients will receive the study drug The primary aim is to compare the all cause mortality with a fixed threshold at Day 42.

CONDITIONS

Official Title

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Patients With Invasive Mold Infections.

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults diagnosed with proven or probable invasive mold infection caused by Aspergillus spp., Fusarium spp., Lomentospora prolificans, Mucorales fungi, or other multidrug-resistant molds
  • Patient's condition allows for appropriate infection source control measures
Not Eligible

You will not qualify if you...

  • Refractory hematologic malignancy
  • Chronic aspergillosis, aspergilloma, or allergic bronchopulmonary aspergillosis
  • COVID-19 associated mucormycosis
  • Invasive fungal disease caused by more than one fungal pathogen (not allowed in Cohort A)
  • Karnofsky Performance Status less than 20 at screening
  • Need for or expected need for hemodialysis, peritoneal dialysis, or hemofiltration
  • Known human immunodeficiency virus infection
  • Ongoing neurological disorders
  • Receiving hospice or comfort care only
  • Other medical or psychiatric conditions
  • Use of any prohibited concomitant medications
  • Current or previous use of an investigational drug within 30 days
  • Prior enrollment in this or any previous fosmanogepix study
  • Moderate or severe liver impairment
  • Pregnancy or lactation
  • Known hypersensitivity to fosmanogepix, manogepix, or their excipients

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 49 locations

1

University of Alabama at Birmingham School of Medicine, Department of Medicine

Birmingham, Alabama, United States, 35294-0006

Actively Recruiting

2

City of Hope

Duarte, California, United States, 91010

Actively Recruiting

3

David Geffen School of Medicine at UCLA

Los Angeles, California, United States, 90095-1690

Actively Recruiting

4

UC Davis Medical Center

Sacramento, California, United States, 95817

Actively Recruiting

5

University of Kentucky Medical Center, Division of Infectious Diseases

Lexington, Kentucky, United States, 40506

Actively Recruiting

6

Johns Hopkins Hospital

Baltimore, Maryland, United States, 21231

Actively Recruiting

7

University of Michigan Health System (UMHS) - A. Alfred Taubman Health Care Center

Ann Arbor, Michigan, United States, 48109-5000

Actively Recruiting

8

Karmanos Cancer Institute - Detroit

Detroit, Michigan, United States, 48201

Actively Recruiting

9

University of Minnesota, M Health Fairview Medical Center

Minneapolis, Minnesota, United States, 55455

Actively Recruiting

10

Washington University School of Medicine, Infectious Diseases Clinical Research Unit

St Louis, Missouri, United States, 63110

Actively Recruiting

11

University of North Carolina at Chapel Hill

Chapel Hill, North Carolina, United States, 27514

Actively Recruiting

12

Duke University Medical Center, Duke Infectious Diseases

Durham, North Carolina, United States, 27710

Actively Recruiting

13

The University of Texas Health Science Center at Houston, Department of Internal Medicine

Houston, Texas, United States, 77030

Actively Recruiting

14

UT MD Anderson Cancer Center

Houston, Texas, United States, 77030

Actively Recruiting

15

Monash Medical Center Clayton

Clayton, Australia, 3168

Actively Recruiting

16

The Alfred Hospital

Melbourne, Australia, 3004

Actively Recruiting

17

Peter MacCallum Cancer Center

Melbourne, Australia, 3050

Actively Recruiting

18

Royal Melbourne Hospital

Parkville, Australia, 3050

Actively Recruiting

19

Princess Alexandra Hospital

Woolloongabba, Australia, 4102

Actively Recruiting

20

Kepler University Hospital GmbH, Department of Internal Medicine IV - Pulmonology

Linz, Austria, 4021

Actively Recruiting

21

Medical University Vienna, Department of Internal Medicine I, Clinical Department of Infections and Tropical Medicine

Vienna, Austria, 1090

Actively Recruiting

22

Charleroi Grand Hospital (GHDC) - Les Viviers Site

Charleroi, Belgium, 6000

Actively Recruiting

23

University Hospitals Leuven, Campus Gasthuisberg, Department of Hematology

Leuven, Belgium, 3000

Actively Recruiting

24

UCL Mont-Godinne University Hospitals

Yvoir, Belgium, 5530

Actively Recruiting

25

University of Alberta

Edmonton, Alberta, Canada, T6G 2R3

Actively Recruiting

26

Juravinski Hospital - Hamilton Health Sciences

Hamilton, Ontario, Canada, L8V 1C3

Actively Recruiting

27

Vancouver Coastal Health Research Institute (VCHRI)

Vancouver, Canada, V5Z 1M9

Actively Recruiting

28

Nantes University Hospital Center - Hotel Dieu Hospital, Department of Infectious and Tropical Diseases

Nantes, France, 44000

Actively Recruiting

29

University Medical Center of Johannes Gutenberg University Mainz

Mainz, Rhineland-Palatinate, Germany, 55131

Actively Recruiting

30

Rambam Health Care Campus, Institute of Infectious Diseases

Haifa, Israel, 3109601

Actively Recruiting

31

Chaim Sheba Medical Center, Department of Infectious Diseases

Ramat Gan, Israel, 52621

Actively Recruiting

32

The Tel Aviv Sourasky Medical Center, Infectious Diseases Unit

Tel Aviv, Israel, 6423906

Actively Recruiting

33

Shamir Medical Center, Department of Infectious Diseases

Ẕerifin, Israel, 7033001

Actively Recruiting

34

Maggiore Polyclinic Hospital, Foundation IRCCS Ca' Granda

Milan, Italy, 20122

Actively Recruiting

35

University Polyclinic Hospital of Modena

Modena, Italy, 41124

Actively Recruiting

36

Polyclinic San Matteo, IRCCS

Pavia, Italy, 27100

Actively Recruiting

37

University Hospital of Pisa

Pisa, Italy, 56126

Actively Recruiting

38

Giuliano Isontina University Health Authority

Trieste, Italy, 34125

Actively Recruiting

39

Radboud University Medical Center (Radboudumc), Department of Intensive Care

Nijmegen, Netherlands, 6525GA

Actively Recruiting

40

Erasmus Medical Center, Deoartment of Infectious Diseases

Rotterdam, Netherlands, 3015 GD

Actively Recruiting

41

University Hospital Virgen Macarena

Seville, Andalusia, Spain, 41009

Actively Recruiting

42

Hospital del Mar, Department of Infectious Diseases

Barcelona, Catalonia, Spain, 08003

Actively Recruiting

43

University Hospital Cruces

Barakaldo, Spain, 48903

Actively Recruiting

44

Hospital de la Santa Creu i Sant Pau

Barcelona, Spain, 08025

Actively Recruiting

45

University Hospital Ramon y Cajal, Department of Infectious Diseases

Madrid, Spain, 28034

Actively Recruiting

46

Faculty of Medicine, Siriraj Hospital

Bangkok, Thailand, 10700

Actively Recruiting

47

Maharaj Nakorn Chiang Mai Hospital

Chiang Mai, Thailand, 50200

Actively Recruiting

48

Songklanagarind Hospital

Hat Yai, Thailand, 90110

Actively Recruiting

49

Srinagarind Hospital

Khon Kaen, Thailand, 40002

Actively Recruiting

Loading map...

Research Team

A

Alison Kuchta, MD

CONTACT

M

Marc Engelhardt, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

3

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here